RU2012136824A - Способы лечения вирусной инфекции гепатита с - Google Patents
Способы лечения вирусной инфекции гепатита с Download PDFInfo
- Publication number
- RU2012136824A RU2012136824A RU2012136824/15A RU2012136824A RU2012136824A RU 2012136824 A RU2012136824 A RU 2012136824A RU 2012136824/15 A RU2012136824/15 A RU 2012136824/15A RU 2012136824 A RU2012136824 A RU 2012136824A RU 2012136824 A RU2012136824 A RU 2012136824A
- Authority
- RU
- Russia
- Prior art keywords
- administered
- patient
- amount
- approximately
- increased
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 108010050904 Interferons Proteins 0.000 claims abstract 9
- 102000014150 Interferons Human genes 0.000 claims abstract 9
- 229940079322 interferon Drugs 0.000 claims abstract 9
- 210000002381 plasma Anatomy 0.000 claims abstract 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims abstract 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims abstract 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 229960000329 ribavirin Drugs 0.000 claims abstract 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims abstract 3
- 210000004185 liver Anatomy 0.000 claims abstract 2
- 230000036470 plasma concentration Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29964310P | 2010-01-29 | 2010-01-29 | |
| US61/299,643 | 2010-01-29 | ||
| US30850610P | 2010-02-26 | 2010-02-26 | |
| US61/308,506 | 2010-02-26 | ||
| US30911710P | 2010-03-01 | 2010-03-01 | |
| US61/309,117 | 2010-03-01 | ||
| US32439510P | 2010-04-15 | 2010-04-15 | |
| US61/324,395 | 2010-04-15 | ||
| PCT/US2011/022854 WO2011094489A1 (en) | 2010-01-29 | 2011-01-28 | Therapies for treating hepatitis c virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012136824A true RU2012136824A (ru) | 2014-03-10 |
Family
ID=43901208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012136824/15A RU2012136824A (ru) | 2010-01-29 | 2011-01-28 | Способы лечения вирусной инфекции гепатита с |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130034522A1 (enExample) |
| EP (1) | EP2528605A1 (enExample) |
| JP (1) | JP2013518124A (enExample) |
| KR (1) | KR20120139699A (enExample) |
| CN (1) | CN102844030A (enExample) |
| AU (1) | AU2011210795A1 (enExample) |
| CA (1) | CA2788348A1 (enExample) |
| IL (1) | IL220937A0 (enExample) |
| MX (1) | MX2012008652A (enExample) |
| RU (1) | RU2012136824A (enExample) |
| SG (1) | SG182589A1 (enExample) |
| TW (1) | TW201130502A (enExample) |
| WO (1) | WO2011094489A1 (enExample) |
| ZA (1) | ZA201205547B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| EP2585448A1 (en) * | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| EA025341B1 (ru) | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Замещенные аналоги нуклеотидов |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100187990B1 (ko) | 1992-12-29 | 1999-06-01 | 스티븐 에프. 웨인스톡 | 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체 |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| TR199802136T2 (xx) | 1996-04-23 | 2001-06-21 | Vertex Pharmaceuticals Incorporated | �MPDH enzimi inhibit�rleri olarak �re t�revleri. |
| ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| ES2405316T3 (es) | 1999-03-19 | 2013-05-30 | Vertex Pharmaceuticals Incorporated | Inhibidores de la enzima IMPDH |
| WO2002000851A2 (en) | 2000-06-28 | 2002-01-03 | National Research Council Of Canada | Helicobacter dd-heptosyltransferase |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| DZ3487A1 (fr) | 2001-01-22 | 2002-07-25 | Merck Sharp & Dohme | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant |
| CN101624391A (zh) | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| SG174624A1 (en) | 2002-08-01 | 2011-10-28 | Pharmasset Inc | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
| CA2413705A1 (en) | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| BRPI0407587A (pt) | 2003-02-18 | 2006-02-14 | Pfizer | inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam |
| JP4682140B2 (ja) | 2003-03-05 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類縁体 |
| EP1601685A1 (en) | 2003-03-05 | 2005-12-07 | Boehringer Ingelheim International GmbH | Hepatitis c inhibiting compounds |
| CA2522577C (en) | 2003-05-21 | 2011-04-26 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| US20050120398A1 (en) | 2003-09-12 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Animal model for HCV infection |
| US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
| UY28525A1 (es) | 2003-09-22 | 2005-04-29 | Boehringer Ingelheim Int | Péptidos macrociclicos activos contra en virus de la hepatitis c |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| TWI368507B (en) | 2004-02-20 | 2012-07-21 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
| WO2005123075A2 (en) | 2004-06-08 | 2005-12-29 | University Of Florida Research Foundation, Inc. | Controlling angiogenesis with anabaseine analogs |
| MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
| CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| US20070225297A1 (en) | 2006-03-16 | 2007-09-27 | Perni Robert B | Deuterated hepatitis C protease inhibitors |
| EA018811B1 (ru) | 2006-03-20 | 2013-10-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом |
| US20070218138A1 (en) | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
| CN102675279A (zh) * | 2006-11-15 | 2012-09-19 | Viro化学制药公司 | 用于治疗或预防黄病毒属感染的噻吩类似物 |
| MX2009006806A (es) | 2006-12-22 | 2009-08-27 | Vertex Pharma | Secado por rocio fluidizado. |
| MX2009009182A (es) | 2007-02-27 | 2009-09-04 | Vertex Pharma | Co-cristales y composiciones farmaceuticas que los comprenden. |
| AU2008254435A1 (en) | 2007-05-21 | 2008-11-27 | Vertex Pharmaceuticals Incorporated | Dose forms comprising VX- 950 and their dosage regimen |
| JP5395068B2 (ja) * | 2007-06-29 | 2014-01-22 | ギリアード サイエンシーズ， インコーポレイテッド | トール様受容体７の調節物質としてのプリン誘導体およびその使用 |
| US8536187B2 (en) * | 2008-07-03 | 2013-09-17 | Gilead Sciences, Inc. | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections |
-
2011
- 2011-01-28 TW TW100103512A patent/TW201130502A/zh unknown
- 2011-01-28 AU AU2011210795A patent/AU2011210795A1/en not_active Abandoned
- 2011-01-28 KR KR1020127021714A patent/KR20120139699A/ko not_active Withdrawn
- 2011-01-28 JP JP2012551302A patent/JP2013518124A/ja active Pending
- 2011-01-28 CA CA2788348A patent/CA2788348A1/en not_active Abandoned
- 2011-01-28 CN CN2011800168308A patent/CN102844030A/zh active Pending
- 2011-01-28 EP EP11703776A patent/EP2528605A1/en not_active Withdrawn
- 2011-01-28 RU RU2012136824/15A patent/RU2012136824A/ru not_active Application Discontinuation
- 2011-01-28 SG SG2012053120A patent/SG182589A1/en unknown
- 2011-01-28 MX MX2012008652A patent/MX2012008652A/es active IP Right Grant
- 2011-01-28 WO PCT/US2011/022854 patent/WO2011094489A1/en not_active Ceased
-
2012
- 2012-07-12 IL IL220937A patent/IL220937A0/en unknown
- 2012-07-23 ZA ZA2012/05547A patent/ZA201205547B/en unknown
- 2012-07-27 US US13/559,995 patent/US20130034522A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011210795A1 (en) | 2012-08-02 |
| US20130034522A1 (en) | 2013-02-07 |
| IL220937A0 (en) | 2012-09-24 |
| EP2528605A1 (en) | 2012-12-05 |
| JP2013518124A (ja) | 2013-05-20 |
| ZA201205547B (en) | 2013-04-24 |
| KR20120139699A (ko) | 2012-12-27 |
| MX2012008652A (es) | 2012-08-23 |
| CN102844030A (zh) | 2012-12-26 |
| CA2788348A1 (en) | 2011-08-04 |
| TW201130502A (en) | 2011-09-16 |
| SG182589A1 (en) | 2012-08-30 |
| WO2011094489A1 (en) | 2011-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| JP2011519364A5 (enExample) | ||
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| JP2013518124A5 (enExample) | ||
| BG106906A (bg) | Пуринови производни | |
| JP2008518943A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| EA201490903A1 (ru) | Композиции и способы лечения вирусного гепатита c | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| MX2010013522A (es) | Uso de telaprevir en combinacion con interferon pegilado y ribavirina para tratar el virus de la hepatitis c. | |
| RU2006107566A (ru) | Способ лечения вирусных инфекций | |
| JP2016153402A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| JP6110791B2 (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| WO2011135743A1 (ja) | Ｃ型肝炎の予防及び／又は治療のための医薬 | |
| RU2014116988A (ru) | Алиспоривир для лечения инфекции, вызванной вирусом гепатита с | |
| US20150174194A1 (en) | Methods for treating liver transplant recipients | |
| RU2012109938A (ru) | Способ лечения вирусного гепатита с | |
| RU2013150344A (ru) | Лечение инфекции вируса гепатита алисповиром | |
| Sabbatani et al. | Overwhelming diffuse psoriasis during chronic HCV infection, after peginterferon-ribavirin treatment, supported by frequent resort to filgrastim rescue | |
| CN103127511A (zh) | 治疗丙型肝炎的新型药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150624 |